Edition:
United Kingdom

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

312.95DKK
20 Aug 2018
Change (% chg)

kr.2.95 (+0.95%)
Prev Close
kr.310.00
Open
kr.310.00
Day's High
kr.313.05
Day's Low
kr.308.05
Volume
1,790,724
Avg. Vol
2,767,904
52-wk High
kr.354.80
52-wk Low
kr.278.15

Select another date:

Wed, Aug 8 2018

Photo

Drugmaker Novo Nordisk sales disappoint, sees lower 2019 U.S. prices

COPENHAGEN Shares in Novo Nordisk fell on Wednesday after sales of some of its key drugs in the second quarter fell short of expectations and it said prices in the key U.S. market would be lower next year.

UPDATE 2-Drugmaker Novo Nordisk sales disappoint, sees lower 2019 U.S. prices

* Keeps 2018 outlook in local currencies, lifts in Danish crowns

Novo Nordisk sees lower U.S. prices next year, Q2 profit in line with forecasts

COPENHAGEN, Aug 8 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, posted second-quarter operating profit broadly in line with forecasts on Wednesday, but said prices in the key U.S. market would be lower next year.

RPT-Novo's Xultophy as add-on treatment shows better blood sugar improvement than Lantus

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk on Saturday presented findings from the DUAL IX study at the American Diabetes Association's 78th Scientific Sessions.

Novo reveals more Ozempic data on change in body weight by baseline BMI

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.

Novo's Xultophy as add-on treatment shows better blood sugar improvement than Lantus

COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk on Saturday presented findings from the DUAL IX study at the American Diabetes Association's 78th Scientific Sessions.

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN, June 21 Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

Novo Nordisk shares fall after report of layoffs

COPENHAGEN Shares in Novo Nordisk opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets.

Novo Nordisk considers laying-off up to 3,000 staff - Danish paper Borsen

COPENHAGEN, June 7 Novo Nordisk is considering laying-off up to 3,000 staff and dropping its long-term financial targets due to challenging market conditions in the United States, Danish daily Borsen reported Thursday citing unnamed sources.

Select another date: